In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.
Healthcare takes the concept of ‘defensive’ further than almost any industry, encompassing many companies that provide patient care, engage in the research and development of new treatments, and design, manufacture, and market diagnostic equipment and tests. Breakthroughs in medical technology, pharmaceuticals, and treatment methods have transformed patient outcomes, with pharmaceutical companies, in particular, attracting significant attention as the demand for rapid results has increased. A report from Grand View Research estimates that the global pharmaceutical manufacturing market was valued at around $516.48 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.63% from 2023 to 2030.
Today, the biopharma sector boasts its largest and most diverse clinical pipeline to date—a result of decades of pioneering research. The number of unique drugs in development has nearly doubled, growing from 3,200 in 2012 to 6,100 in 2022. That said, only 14% of drugs in clinical trials make it to FDA approval, according to Research from MIT, pushing the average cost of developing a single drug to about $1 billion. AI could be the game-changer here. Generative AI, for example, lets researchers explore way more potential compounds than traditional methods can while helping spot disease patterns in massive data sets to find the best drug combinations. Moreover, PwC predicts that AI-driven automation and analytics could slash process timelines by 60–70% and reduce operational costs by over 30%.
See also: 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds.
Similarly, interest in weight-loss drugs like Ozempic and Wegovy has fueled huge growth in the industry. A recent study published in the scientific journal Addiction indicates that GLP-1 drugs could cut opioid and alcohol addiction rates by up to half. These drugs are also being tested for Alzheimer’s and other conditions commonly linked to obesity. For pharmaceutical companies aiming to lead in areas like cardiovascular and renal health, developing GLP-1s is becoming essential. The focus has shifted beyond competing with the top dogs in the anti-obesity market, which is projected to reach $130 billion by 2030. As the potential applications of GLP-1s grow, so does the opportunity for new players to enter the field. Swiss company Roche, for instance, rejoined the race for a weight-loss pill last year with its acquisition of California-based Carmot Therapeutics for up to $3.1 billion. The company is looking to “fast-track” its anti-obesity treatments, aiming to capture a chunk of the weight-loss market and restore confidence in its pipeline.
Headwinds in Pharmaceuticals
At first glance, the pharma industry might look like it’s thriving. But, like any industry, it faces its own set of challenges. Both biotech and pharmaceuticals faced a steep 48.6% decline in funding last year compared to 2021. The IPO market also dropped sharply in 2022, with proceeds plummeting amid market instability and volatility. The surge in drug-developer IPOs in 2020 and 2021, which raised approximately $46.5 billion—surpassing the total from the previous eight years combined—left many general investors wary. The biotech industry’s high-risk, high-reward nature, coupled with macroeconomic and geopolitical risks affecting broader markets, has put upcoming IPOs under close scrutiny. That said, drug developers have managed to raise $2 billion through IPOs this year as of September 3, reflecting a 24% increase compared to the same period in 2023. Though nearly two-thirds of these funds were secured in the initial two months amid a surge of new listings, according to BNN Bloomberg. However, with less than $800 million raised in the following six months, drug developers’ share of U.S. IPO proceeds has dropped from 17% in February to 6.5%.
In his welcome remarks at the October 7 conference, Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), highlighted a rise in investment in cell and gene therapies in 2024. He noted that 13 of the world’s 15 largest pharma companies by market capitalization now have an “active presence” in this field. With numerous product patents set to expire, major pharmaceutical companies are increasingly looking to cell and gene therapies to bridge potential revenue gaps. Despite this interest, the number of cell and gene therapy deals in the pharma sector dropped by 38% in Q2 2024 compared to the same period in 2023, and there has been a decline in related patent applications. That said, the industry remains compelling and is one that potential investors shouldn’t ignore.
Pixabay/Public Domain
Our Methodology
We began by examining several U.S. pharmaceutical ETFs to identify stocks with the highest weightings. From these selections, we ranked each stock based on the total number of hedge fund holders as of Q2 2024.
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here)
10. Bristol-Myers Squibb Company (NYSE:BMY)
Number of Hedge Fund Holders: 61
Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company involved in the research, development, licensing, manufacturing, marketing, and distribution of its products. Earlier this year, BMY completed a $14 billion acquisition of Karuna Therapeutics, gaining access to its experimental psychosis treatment, KarXT.
On October 31, Bristol-Myers Squibb Company (NYSE:BMY) reported third-quarter earnings and revenue that exceeded Wall Street’s expectations, driven by strong performance from its blockbuster blood thinner Eliquis and a lineup of key drugs aimed at long-term growth. These results come as the biopharma giant targets $1.5 billion in cost savings by the end of 2025, which it plans to reinvest in core drug brands and R&D. Revenue also rose 8% year-over-year to $11.89 billion, and the company raised its full-year revenue forecast, anticipating around a 5% increase in sales.
On September 29, BMO Capital raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) from $48 to $53, maintaining a Market Perform rating. This update came after the approval of COBENFY, a new drug by BMY priced at $1,850 for a 30-day supply, or around $22,500 annually before rebates or discounts. The approval, which comes without a boxed warning, validates Bristol-Myers Squibb’s $12.7 billion acquisition of Karuna, the drug’s original developer.
9. Gilead Sciences, Inc. (NASDAQ:GILD)
Number of Hedge Fund Holders: 62
Based in Foster City, California, Gilead Sciences, Inc. (NASDAQ:GILD) is a U.S. biopharmaceutical company focused on developing antiviral treatments for diseases like HIV/AIDS, hepatitis B and C, influenza, and COVID-19.
Despite challenges in its solid tumor oncology division, Gilead Sciences, Inc. (NASDAQ:GILD) has an Outperform rating from BMO Capital, underscoring the firm’s positive view of Gilead’s broader business potential. Analysts at TD Cowen and Leerink Partners also reaffirmed their Buy and Outperform ratings, with Leerink upgrading the stock following strong Phase 3 results for Gilead’s HIV drug, lenacapavir.
In a Phase 3 trial, lenacapavir showed a massive 96% reduction in HIV infections, and Gilead Sciences, Inc. (NASDAQ:GILD) plans to file for approval by the end of 2024. The company also posted a 6% year-over-year growth in total product sales, driven by an 8% increase in sales of its HIV treatment Biktarvy and a 23% rise for its oncology drug, Trodelvy.
According to Insider Monkey, 62 hedge funds held stakes in Gilead Sciences, Inc. (NASDAQ:GILD) at the end of the second quarter of 2024.
Parnassus Investments mentioned Gilead Sciences, Inc. (NASDAQ:GILD) in its Q1 2024 investor letter. Here is what the fund said:
“Gilead Sciences, a global biopharmaceutical company, saw its shares decline as a cancer drug failed to expand into additional lung indications, denting investor faith in the company’s oncology franchise. We maintain confidence in Gilead’s core HIV franchise and ability to expand into cancer treatment portfolios.”
